Skip to content

Author

Rudolf A. Werner

5 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Influence of increased injected activities up 9.0 GBq [177Lu]Lu-PSMA-I&T on absorbed doses to lesions and kidneys

Administration activities of 177Lu-PSMA were chosen cautiously in the treatment of advanced prostate cancer. The primary aim was to investigate the association between increased injected activities, and the calculated absorbed doses (AD). In this single center, retrospective analysis, patients with PSMA-avid metastatic...

Z. Ells, Linus Hempel, J. Ells et al. · 0 citations
Open access Oct 2026

Organ-specific depth of response to CD19-directed CAR T-cell therapy in B-cell lymphomas

CD19-directed chimeric antigen receptor T cell therapy (CART) has transformed treatment of relapsed or refractory (r/r) large B cell lymphoma (LBCL); however, organ-specific response patterns and depth of response (DoR) remain insufficiently characterized. This study evaluated organ-specific imaging response and the im...

M. Kassube, P. Achhammer, Philipp Linden et al. · 0 citations
Open access Oct 2026

Long-term effects of [177Lu]Lu-PSMA therapy on the kidneys based on cumulative absorbed dose

177 Lu-PSMA radiopharmaceutical therapy shows favorable clinical responses for metastatic castration-resistant prostate cancer patients but may cause radiation-induced kidney damage due to specific and nonspecific activity accumulation. We evaluated the association between cumulative kidney absorbed doses and...

Z. Ells, Mu-Yu Wu, Linus Hempel et al. · 0 citations
Sep 2026

Identification of prognostically relevant residual tumor in glioblastoma after surgery: A comparative analysis of MR-based RANO resect classes vs. [18F]FET PET.

BACKGROUND Assessment of postoperative tumor burden is essential in IDH-wildtype glioblastoma. The RANO resect classification stratifies patients based on residual tumor volume on postoperative MRI. [¹⁸F]FET PET can detect metabolically active tumor-suspicious tissue invisible on MRI. Its additional prognostic contribu...

J. Blobner, Katharina J. Schmidbauer, M. Müther et al. · 0 citations
Open access Sep 2026

PSMA PET/CT-guided salvage elective nodal radiotherapy for nodal metastases after radical prostatectomy: a bi-institutional long-term outcome analysis.

PURPOSE PSMA PET/CT has transformed the detection of nodal recurrence after radical prostatectomy, yet real-world evidence on long-term outcomes of PSMA PET/CT-guided salvage elective nodal radiotherapy (ENRT) remains limited. This study evaluated oncological outcomes of PSMA PET/CT-guided salvage ENRT in a bi-institut...

S. Vorbach, Thomas Seppi, Giulia Santo et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.